Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 11, 2010, Pages 1287-1297

  Kim, Seaho ^a,b   Huang, Wei ^a,b   Mottillo, Emilio P ^a,b   Sohail, Anjum ^a,b   Ham, Yoon Ah ^a,b   Conley LaComb, M Katie ^a,b   Kim, Chong Jai ^a,b   Tzivion, Guri ^a,b   Kim, Hyeong Reh Choi ^a,b   Wang, Shihua ^c   Chen, Yong Q ^c   Fridman, Rafael ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Glycosylation; Matrix metalloproteinases; Posttranslational modification; Prostate cancer; PTEN

Indexed keywords

COLLAGEN; MATRIX METALLOPROTEINASE 14; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INVASION; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE DELETION; GENE LOSS; GLYCOSYLATION; HETEROZYGOTE; HOMOZYGOTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; ENZYME ACTIVATION; ENZYME PRECURSORS; EPITHELIAL CELLS; GELATINASES; GENE EXPRESSION PROFILING; GENOTYPE; GLYCOSYLATION; HUMANS; IMMUNOBLOTTING; MALE; MATRIX METALLOPROTEINASE 14; MICE; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIROLIMUS;

MUS;

EID: 77956476631     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2010.06.011     Document Type: Article

References (71)

1. Massova I., Kotra L.P., Fridman R., Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998, 12:1075-1095.
2. Zucker S., Pei D., Cao J., Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr. Top. Dev. Biol. 2003, 54:1-74.
3. Osenkowski P., Toth M., Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J. Cell. Physiol. 2004, 200:2-10.
4. Itoh Y. MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 2006, 58:589-596.
5. Itoh Y., Ito N., Nagase H., Evans R.D., Bird S.A., Seiki M. Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol. Biol. Cell 2006, 17:5390-5399.
6. Itoh Y., Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol. 2006, 206:1-8.
7. Remacle A.G., Chekanov A.V., Golubkov V.S., Savinov A.Y., Rozanov D.V., Strongin A.Y. O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP). J. Biol. Chem. 2006, 281:16897-16905.
8. Wu Y.I., Munshi H.G., Sen R., Snipas S.J., Salvesen G.S., Fridman R., Stack M.S. Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J. Biol. Chem. 2004, 279:8278-8289.
9. Nyalendo C., Michaud M., Beaulieu E., Roghi C., Murphy G., Gingras D., Beliveau R. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J. Biol. Chem. 2007, 282:15690-15699.
10. Anilkumar N., Uekita T., Couchman J.R., Nagase H., Seiki M., Itoh Y. Palmitoylation at Cys574 is essential for MT1-MMP to promote cell migration. FASEB J. 2005, 19:1326-1328.
11. Zhao H., Sohail A., Sun Q., Shi Q., Kim S., Mobashery S., Fridman R. Identification and role of the homodimerization interface of the glycosylphosphatidylinositol-anchored membrane type 6 matrix metalloproteinase (MMP25). J. Biol. Chem. 2008, 283:35023-35032.
12. Hotary K., Li X.Y., Allen E., Stevens S.L., Weiss S.J. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev. 2006, 20:2673-2686.
13. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., Weiss S.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003, 114:33-45.
14. Bonfil R.D., Dong Z., Trindade Filho J.C., Sabbota A., Osenkowski P., Nabha S., Yamamoto H., Chinni S.R., Zhao H., Mobashery S., Vessella R.L., Fridman R., Cher M.L. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am. J. Pathol. 2007, 170:2100-2111.
15. Jennbacken K., Gustavsson H., Welen K., Vallbo C., Damber J.E. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 2006, 66:1631-1640.
16. Udayakumar T.S., Chen M.L., Bair E.L., Von Bredow D.C., Cress A.E., Nagle R.B., Bowden G.T. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res. 2003, 63:2292-2299.
17. Cao J., Chiarelli C., Kozarekar P., Adler H.L. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis. Thromb. Haemost. 2005, 93:770-778.
18. Wang X., Wilson M.J., Slaton J.W., Sinha A.A., Ewing S.L., Pei D. Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP). J. Androl. 2009, 30:259-274.
19. Cao J., Chiarelli C., Richman O., Zarrabi K., Kozarekar P., Zucker S. Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J. Biol. Chem. 2008, 283:6232-6240.
20. Cardillo M.R., Di Silverio F., Gentile V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res. 2006, 26:973-982.
21. Trudel D., Fradet Y., Meyer F., Harel F., Tetu B. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum. Pathol. 2008, 39:731-739.
22. Upadhyay J., Shekarriz B., Nemeth J.A., Dong Z., Cummings G.D., Fridman R., Sakr W., Grignon D.J., Cher M.L. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin. Cancer Res. 1999, 5:4105-4110.
23. Dahia P.L. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer 2000, 7:115-129.
24. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., Isaacs W.B., Bova G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998, 58:204-209.
25. Wang S.I., Parsons R., Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. 1998, 4:811-815.
26. McCall P., Witton C.J., Grimsley S., Nielsen K.V., Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer?. Br. J. Cancer 2008, 99:1296-1301.
27. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
28. Yoshimoto M., Cunha I.W., Coudry R.A., Fonseca F.P., Torres C.H., Soares F.A., Squire J.A. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer 2007, 97:678-685.
29. McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59:4291-4296.
30. Han B., Mehra R., Lonigro R.J., Wang L., Suleman K., Menon A., Palanisamy N., Tomlins S.A., Chinnaiyan A.M., Shah R.B. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 2009, 22:1083-1093.
31. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., Cordon-Cardo C., Pandolfi P.P. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003, 1:E59.
32. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., Liu X., Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4:209-221.
33. Berquin I.M., Min Y., Wu R., Wu J., Perry D., Cline J.M., Thomas M.J., Thornburg T., Kulik G., Smith A., Edwards I.J., D'Agostino R., Zhang H., Wu H., Kang J.X., Chen Y.Q. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J. Clin. Invest. 2007, 117:1866-1875.
34. Zhao H., Bernardo M.M., Osenkowski P., Sohail A., Pei D., Nagase H., Kashiwagi M., Soloway P.D., DeClerck Y.A., Fridman R. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J. Biol. Chem. 2004, 279:8592-8601.
35. Barclay W.W., Cramer S.D. Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate 2005, 63:291-298.
36. Barclay W.W., Axanova L.S., Chen W., Romero L., Maund S.L., Soker S., Lees C.J., Cramer S.D. Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells 2008, 26:600-610.
37. Cho J.A., Osenkowski P., Zhao H., Kim S., Toth M., Cole K., Aboukameel A., Saliganan A., Schuger L., Bonfil R.D., Fridman R. The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP. J. Biol. Chem. 2008, 283:17391-17405.
38. Toth M., Gervasi D.C., Fridman R. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res. 1997, 57:3159-3167.
39. Hotary K., Allen E., Punturieri A., Yana I., Weiss S.J. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol. 2000, 149:1309-1323.
40. Ludwig T., Theissen S.M., Morton M.J., Caplan M.J. The cytoplasmic tail dileucine motif LL572 determines the glycosylation pattern of membrane-type 1 matrix metalloproteinase. J. Biol. Chem. 2008, 283:35410-35418.
41. Wu Y.I., Munshi H.G., Snipas S.J., Salvesen G.S., Fridman R., Stack M.S. Activation-coupled membrane-type 1 matrix metalloproteinase membrane trafficking. Biochem. J. 2007, 407:171-177.
42. Hernandez-Barrantes S., Bernardo M., Toth M., Fridman R. Regulation of membrane type-matrix metalloproteinases. Semin. Cancer Biol. 2002, 12:131-138.
43. Gervasi D.C., Raz A., Dehem M., Yang M., Kurkinen M., Fridman R. Carbohydrate-mediated regulation of matrix metalloproteinase-2 activation in normal human fibroblasts and fibrosarcoma cells. Biochem. Biophys. Res. Commun. 1996, 228:530-538.
44. Wilson M.J., Jiang A., Wiehr C., Wang X., Sinha A.A., Pei D. Limited processing of pro-matrix metalloprotease-2 (gelatinase A) overexpressed by transfection in PC-3 human prostate tumor cells: association with restricted cell surface localization of membrane-type matrix metalloproteinase-1. J. Androl. 2004, 25:274-285.
45. Sabeh F., Li X.Y., Saunders T.L., Rowe R.G., Weiss S.J. Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J. Biol. Chem. 2009, 284:23001-23011.
46. Chiang G.G., Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13:433-442.
47. Holz M.K., Ballif B.A., Gygi S.P., Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005, 123:569-580.
48. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65:7052-7058.
49. Ahmad I., Sansom O.J., Leung H.Y. Advances in mouse models of prostate cancer. Expert Rev. Mol. Med. 2008, 10:e16.
50. Ratnacaram C.K., Teletin M., Jiang M., Meng X., Chambon P., Metzger D. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 2008, 105:2521-2526.
51. Osenkowski P., Meroueh S.O., Pavel D., Mobashery S., Fridman R. Mutational and structural analyses of the hinge region of membrane type 1-matrix metalloproteinase and enzyme processing. J. Biol. Chem. 2005, 280:26160-26168.
52. Ohtsubo K., Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126:855-867.
53. Hess A.R., Seftor E.A., Seftor R.E., Hendrix M.J. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 2003, 63:4757-4762.
54. Ispanovic E., Haas T.L. JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells. Am. J. Physiol. Cell Physiol. 2006, 291:C579-C588.
55. Zahradka P., Harding G., Litchie B., Thomas S., Werner J.P., Wilson D.P., Yurkova N. Activation of MMP-2 in response to vascular injury is mediated by phosphatidylinositol 3-kinase-dependent expression of MT-1 MMP (MMP-14). Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H2861-H2870.
56. Sroka I.C., Nagle R.B., Bowden G.T. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia 2007, 9:406-417.
57. Zhang D., Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003, 22:974-982.
58. Suzuki A., Lu J., Kusakai G., Kishimoto A., Ogura T., Esumi H. ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol. Cell. Biol. 2004, 24:3526-3535.
59. Chen W.S., Xu P.Z., Gottlob K., Chen M.L., Sokol K., Shiyanova T., Roninson I., Weng W., Suzuki R., Tobe K., Kadowaki T., Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001, 15:2203-2208.
60. Ulici V., Hoenselaar K.D., Agoston H., McErlain D.D., Umoh J., Chakrabarti S., Holdsworth D.W., Beier F. The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. Bone 2009, 45:1133-1145.
61. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
62. Laplante M., Sabatini D.M. mTOR signaling at a glance. J. Cell Sci. 2009, 122:3589-3594.
63. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell. Biol. 2009, 10:307-318.
64. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
65. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
66. Wang X., Yue P., Kim Y.A., Fu H., Khuri F.R., Sun S.Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res. 2008, 68:7409-7418.
67. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
68. Shi Y., Yan H., Frost P., Gera J., Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 2005, 4:1533-1540.
69. S.A. Lang, C. Hackl, C. Moser, S. Fichtner-Feigl, G.E. Koehl, H.J. Schlitt, E.K. Geissler, O. Stoeltzing, Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells, Biochim Biophys Acta 1803 (2010) 435-442.
70. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
71. Grant S. Cotargeting survival signaling pathways in cancer. J. Clin. Invest. 2008, 118:3003-3006.